Skip to main content
SpringerLink
Log in

Role of Anti-HER2/Neu Molecules in the Management of HER2-Positive Early Breast Cancer

  • Chapter
  • First Online:
Management of Early Stage Breast Cancer

  • 871 Accesses

Abstract

Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% of breast cancers and is usually linked to a more aggressive natural history with poor response rates and decreased survival [1]. HER2-targeted therapies have changed this landscape as has been proven by an improvement in progression-free survival (PFS) and overall survival (OS) with the addition of trastuzumab as compared to chemotherapy in patients with early as well as advanced disease [2]. Although survival rates have improved after the use of trastuzumab, still we are unable to predict the response to treatment. Further understanding of the biology of HER2-positive breast cancer would help in choosing the most suitable treatment regimen for our patients and in developing new ways to combat HER2 resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Moasser MM, Krop IE. The evolving landscape of HER2 targeting in breast cancer. JAMA Oncol. 2015;1:1154–61.

    Article  Google Scholar 

  2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  CAS  Google Scholar 

  3. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;61(Suppl 2):1–13.

    Article  CAS  Google Scholar 

  4. Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015;66:111–28.

    Article  CAS  Google Scholar 

  5. Wuerstlein R, Harbeck N. Neoadjuvant therapy for HER2-positive breast cancer. Rev Recent Clin Trials. 2017;12:81–92.

    Article  CAS  Google Scholar 

  6. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al.; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633–640.

    Google Scholar 

  7. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.

    Article  CAS  Google Scholar 

  8. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278–84.

    Article  CAS  Google Scholar 

  9. Loibl S, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, et al.; Investigators of the German Breast Group (GBG) and the Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) studygroups. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol. 2017;28:497–504.

    Google Scholar 

  10. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115–26.

    Article  CAS  Google Scholar 

  11. Whitworth P, Stork-Sloots L, de Snoo FA, Richards P, Rotkis M, Beatty J, et al. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). Ann Surg Oncol. 2014;21:3261–7.

    Article  Google Scholar 

  12. van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Dutch Breast Cancer Research Group (BOOG). Lancet Oncol. 2018;19:1630–40.

    Article  Google Scholar 

  13. Yu AF, Singh JC, Wang R, Liu JE, Eaton A, Oeffinger KC, et al. Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer. Oncologist. 2017;22:642–7.

    Article  CAS  Google Scholar 

  14. Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13:620–30.

    Article  CAS  Google Scholar 

  15. Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, et al. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat. 2019;173:1–9.

    Article  CAS  Google Scholar 

  16. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2019;37:1868–75.

    Article  CAS  Google Scholar 

  17. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al.; KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28.

    Google Scholar 

  18. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2 positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol. 2016;34:1034–42.

    Article  CAS  Google Scholar 

  19. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al.; ExteNET StudyGroup. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1688-1700.

    Google Scholar 

  20. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer; APHINITY Steering Committee and Investigators. N Engl J Med. 2017;377:122–31.

    Article  Google Scholar 

  21. Niraula S, Gyawali B. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2019;173:103–9.

    Article  CAS  Google Scholar 

  22. Esposito A, Viale G, Criscitiello C, Curigliano G. Clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. Expert Rev Clin Pharmacol. 2019;12:9–16.

    Article  CAS  Google Scholar 

  23. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389:1195–2105.

    Article  CAS  Google Scholar 

  24. Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009;27:5685–92.

    Article  CAS  Google Scholar 

  25. Schneider BP, O’Neill A, Shen F, Sledge GW, Thor AD, Kahanic SP, et al. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer. 2015;113:1651–7.

    Article  CAS  Google Scholar 

  26. Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol. 2018;4:1199–206.

    Article  Google Scholar 

  27. Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, et al.; Reader study level-I and level-II Groups. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Ann Oncol. 2018;29:2328–2333.

    Google Scholar 

  28. Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14:741–8.

    Article  CAS  Google Scholar 

  29. Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015;26:1333–40.

    Article  CAS  Google Scholar 

  30. Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, et al.; PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393:2599–2612.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India

    K. Pavithran

Authors
  1. K. Pavithran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Pavithran .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham University, Kochi, Kerala, India

    Beena Kunheri

  2. Department of Breast and Gynecological Oncology, Amrita Institute of Medical Sciences Amrita Vishwa Vidyapeetham University, Kochi, Kerala, India

    D. K. Vijaykumar

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pavithran, K. (2021). Role of Anti-HER2/Neu Molecules in the Management of HER2-Positive Early Breast Cancer. In: Kunheri, B., Vijaykumar, D.K. (eds) Management of Early Stage Breast Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-15-6171-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-6171-9_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-6170-2

  • Online ISBN: 978-981-15-6171-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation